The SwirlGraft vascular access graft has undergone scientific trials at six hospitals in the Netherlands. During 2005 SwirlGraft was granted regulatory approvals in the Europe and US. This funding round will be used to develop the SwirlGraft and specifically to finance further clinical trials for the united states market. Mark White colored , Director of Invention & Creativity at NESTA, stated: Veryan Medical is a great example of the type of UK innovation our early stage seed funding is made to support. Through buying its innovative technology early on we are searching to ensure that this notion has every opportunity of being fully commercialised, benefiting individuals, those working in healthcare, and the united kingdom economy.These data, published on-line in Investigative Ophthalmology & Visible Research , demonstrate the power of aganirsen to attain and exert activity on the retina. Related StoriesResearchers identify tumor suppressor genes that get subset of melanomasImproved gene therapy treatment shows promise in mice with cystic fibrosisRNA-based medicines provide many advantages over CRISPR/Cas9 gene editing system’Age-related macular degeneration and ischemic retinopathies are major causes of blindness that are associated with neovascularisation.